RETRACTED: Mutation Analysis of EGFR Gene in Patients with Non-Small Cell Lung Cancer in Xinjiang

DOI: 10.4236/ijcm.2020.114015   PDF   HTML     88 Downloads   183 Views  

Abstract

Short Retraction Notice 

International Journal of Clinical Medicine (IJCM) does not meet authors’ publication requirements. 

This article has been retracted to straighten the academic record. In making this decision the Editorial Board follows COPE's Retraction Guidelines. The aim is to promote the circulation of scientific research by offering an ideal research publication platform with due consideration of internationally accepted standards on publication ethics. The Editorial Board would like to extend its sincere apologies for any inconvenience this retraction may have caused. Please see the article page for more details. The full retraction notice in PDF is preceding the original paper which is marked "RETRACTED".

Share and Cite:

  

Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

References

[1] Seow, W.J., Matsuo, K., Hsiung, C.A., et al. (2017) Association between GWAS-Identified Lung Adenocarcinoma Susceptibility Loci and EGFR Mutations in Never-Smoking Asian Women, and Comparison with Findings from Western Populations. Human Molecular Genetics, 26, 454-465.
[2] Da Cunha Santos, G., Shepherd, F.A. and Tsao, M.S. (2011) EGFR Mutations and Lung Cancer. Annual Review of Pathology, 6, 49-69.
https://doi.org/10.1146/annurev-pathol-011110-130206
[3] Bao, M.X., Jing, C. and Duan, D. (2005) Identification of EGFR Kinase Domain Mutations among Lung Cancer Patients in China: Implication for Targeted Cancer Therapy. Cell Research, 15, 212.
https://doi.org/10.1038/sj.cr.7290289
[4] Yuh, M. (2013) Usage of EGFR-TKI and WBRT in NSCLC Patients with Brain Metastases. Annals of Palliative Medicine, 2, 108-110.
[5] Fan, Y., Xu, X. and Xie, C. (2014) EGFR-TKI Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: A Pooled Analysis of Published Data. OncoTargets and Therapy, 7, 2075-2084.
https://doi.org/10.2147/OTT.S67586
[6] Roskoski, R. (2019) Small Molecule Inhibitors Targeting the EGFR/ErbB Family of Protein-Tyrosine Kinases in Human Cancers. Pharmacological Research, 139, 395-411.
https://doi.org/10.1016/j.phrs.2018.11.014
[7] Li, Y., Appius, A., Pattipaka, T., et al. (2019) Real-World Management of Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small-Cell Lung Cancer in the USA. PLoS ONE, 14, e0209709.
https://doi.org/10.1371/journal.pone.0209709
[8] Ahn, M.J., Kim, S.W., Cho, B.C., et al. (2014) Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea with Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR. Oncologist, 19, 702-703.
https://doi.org/10.1634/theoncologist.2013-0419
[9] Schuette, W., Schirmacher, P., Eberhardt, W.E., et al. (2015) EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non-Small Cell Lung Cancer in Germany: An Observational Study. Cancer Epidemiology, Biomarkers & Prevention, 24, 1254-1261.
https://doi.org/10.1158/1055-9965.EPI-14-1149
[10] Chen, W., Zheng, R., Zeng, H., et al. (2015) Epidemiology of Lung Cancer in China. Thoracic Cancer, 6, 209-215.
https://doi.org/10.1111/1759-7714.12169
[11] Agustoni, F., Suda, K., Yu, H., et al. (2019) EGFR-Directed Monoclonal Antibodies in Combination with Chemotherapy for Treatment of Non-Small-Cell Lung Cancer: An Updated Review of Clinical Trials and New Perspectives in Biomarkers Analysis. Cancer Treatment Reviews, 72, 15-27.
https://doi.org/10.1016/j.ctrv.2018.08.002
[12] Takanashi, Y., Tajima, S., Hayakawa, T., et al. (2016) Pulmonary Micropapillary-Type Adenosquamous Carcinoma Sharing Epidermal Growth Factor Receptor Mutation in Adenocarcinoma and Squamous Cell Carcinoma. Respirology Case Reports, 4, e00179.
https://doi.org/10.1002/rcr2.179
[13] Wang, Z., Li, Z., Ding, X., et al. (2015) ERbeta Localization Influenced Outcomes of EGFR-TKI Treatment in NSCLC Patients with EGFR Mutations. Scientific Reports, 5, 11392.
https://doi.org/10.1038/srep11392
[14] Sasaki, H., Endo, K., Mizuno, K., et al. (2006) EGFR Mutation Status and Prognosis for Gefitinib Treatment in Japanese Lung Cancer. Lung Cancer, 51, 135-136.
https://doi.org/10.1016/j.lungcan.2005.09.004
[15] Zhong, W.-Z., Wang, Q., Mao, W.-M., et al. (2018) Gefitinib versus Vinorelbine plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC (ADJUVANT/CTONG1104): A Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 19, 139-148.
https://doi.org/10.1016/S1470-2045(17)30729-5
[16] Kuiper, J.L., Hashemi, S.M., Thunnissen, E., et al. (2016) Non-Classic EGFR Mutations in a Cohort of Dutch EGFR-Mutated NSCLC Patients and Outcomes Following EGFR-TKI Treatment. British Journal of Cancer, 115, 1504-1512.
https://doi.org/10.1038/bjc.2016.372
[17] Soo, R.A., Kubo, A., Ando, M., et al. (2017) Association between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-Smokers with Non-Small-Cell Lung Cancer: Analyses from a Prospective Multinational ETS Registry. Clinical Lung Cancer, 18, 535-542.
https://doi.org/10.1016/j.cllc.2017.01.005
[18] Kawaguchi, T., Ando, M., Kubo, A., et al. (2011) Long Exposure of Environmental Tobacco Smoke Associated with Activating EGFR Mutations in Never-Smokers with Non-Small Cell Lung Cancer. Clinical Cancer Research, 17, 39-45.
https://doi.org/10.1158/1078-0432.CCR-10-1773
[19] Shi, Y., Siu-Kie Au, J., Thongprasert, S., Chun-Ming, T.M., Karin Heeroma, T.K., et al. (2014) A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER). Journal of Thoracic Oncology, 9, 154-156.
https://doi.org/10.1097/JTO.0000000000000033
[20] Chen, W., Zheng, R., Baade, P.D., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal, 66, 115-132.
https://doi.org/10.3322/caac.21338
[21] Penault-Llorca, F. and Radosevic-Robin, N. (2018) Tumor Mutational Burden in Non-Small Cell Lung Cancer-The Pathologist’s Point of View. Translational Lung Cancer Research, 7, 716-721.
https://doi.org/10.21037/tlcr.2018.09.26
[22] Li, M., Zhang, Q., Liu, L., et al. (2011) The Different Clinical Significance of EGFR Mutations in Exon 19 and 21 in Non-Small Cell Lung Cancer Patients of China. Neoplasma, 58, 74-81.
https://doi.org/10.4149/neo_2011_01_74
[23] Wu, Y.-L., Lee, V., Liam, C.-K., et al. (2018) Clinical Utility of a Blood-Based EGFR Mutation Test in Patients Receiving First-Line Erlotinib Therapy in the ENSURE, FASTACT-2, and ASPIRATION Studies. Lung Cancer, 126, 1-8.
https://doi.org/10.1016/j.lungcan.2018.10.004
[24] Benbrahim, Z., Antonia, T. and Mellas, N. (2018) EGFR Mutation Frequency in Middle East and African Non-Small Cell Lung Cancer Patients: A Systematic Review and Meta-Analysis. BMC Cancer, 18, 891.
https://doi.org/10.1186/s12885-018-4774-y
[25] Yang, M.Z., Zhang, L., Bai, J., et al. (2016) The Difference of EGFR Mutation in Uygur and Han’s Non-Small Cell Lung Cancer in Xinjiang, China. Modern Oncology, 24, 404-406.
[26] Gu, G.D., Wang, X. and Liu, C. (2014) Clinical Feature Analysis of 254 Cases of Uygur Lung Cancer Patients in Xinjiang Area. Journal of Clinical Medicine in Practice, 18, 37-38.

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.